Angiotensin-converting enzyme 2 as a therapeutic target for heart failure

Mohammed A.R. Chamsi-Pasha, Zhili Shao, W. H.Wilson Tang

Research output: Contribution to journalArticlepeer-review

88 Scopus citations


The renin-angiotensin system (RAS) plays a major role in the pathophysiology of cardiovascular disorders. Angiotensin II (Ang-II), the final product of this pathway, is known for its vasoconstrictive and proliferative effects. Angiotensin-converting enzyme 2 (ACE2), a newly discovered homolog of ACE, plays a key role as the central negative regulator of the RAS. It diverts the generation of vasoactive Ang-II into the vasodilatory and growth inhibiting peptide angiotensin(1-7) [Ang(1-7)], thereby providing counter-regulatory responses to neurohormonal activation. There is substantial experimental evidence evaluating the role of ACE2/Ang(1-7) in hypertension, heart failure, and atherosclerosis. In this review, we aim to focus on the conceptual facts of the ACE2-Ang(1-7) axis with regards to clinical implications and therapeutic targets in cardiovascular disorders, with emphasis on the potential therapeutic role in cardiovascular diseases.

Original languageEnglish (US)
Pages (from-to)58-63
Number of pages6
JournalCurrent heart failure reports
Issue number1
StatePublished - Mar 2014


  • Angiotensin (1-7)
  • Angiotensin converting enzyme 2
  • Heart failure
  • Renin angiotensin system

ASJC Scopus subject areas

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Angiotensin-converting enzyme 2 as a therapeutic target for heart failure'. Together they form a unique fingerprint.

Cite this